Title Image

Psoriasis eczema dermatitis

Launched or under launch (2013-2014): Australia & New Zealand, Canada, Djibouti, Dubai, Egypt, Ivory Coast, Jordan, Lebanon, Libya, Malaysia, Mauritania, Middle East, Moldavia & Montenegro, Romania, Serbia, South Africa, Tunisia.

VB-DERM

50mL Class IIa Medical Device for the treatment of Lesions
of Psoriasis, Eczema & Dermatitis (Official Indication)

PSORIASIS, ECZEMA, DERMATITIS (PED)

Physiopathology: Although Psoriasis, Eczema & Dermatitis are classified as different diseases, all histological sections of PE&D lesions show a common picture: excessive & uncontrolled growth of dermal cells, very high numbers of cytokine-secreting immunological cells, inflammation & secondary microbial contamination. Vitrobio identified >8 cytokines acting as cell growth factors, inducing inflammation, & maintaining the excessive cell growth caused by the cytokine cascade.

Ideal Treatment Approach: As autoimmune dysfunctions cannot presently be treated, normalizing cell growth by identifying & stopping the abnormal activity of growth factor-like cytokines is the only symptomatic treatment to ease symptoms of the disease.

Currently Available Treatments

  • Topical cell growth regulators: none
  • All the currently available treatments such as: anti-inflammatory drugs, corticosteroids, Vitamin A & D analogues, immune-modulators, immune-suppressants, as well as specific inhibitors of T-cells or leukocytes, interleukin inhibitors, TNF-alpha blockers, and anti-mitotic drugs, are directed to block only one or two cytokines or cellular functions, whereas their systemic presence induces serious side effects.

VITROBIO’s Completely NEW Therapeutic Approach:

VITROBIO discovered and patented a viscous liquid, 18 times more osmotically active than sea water yet NON-IRRITANT (VB-Gy – PCT/FR99/01340). For a prolonged activity, VB-Gy was rendered filmogen using specific plant polymers (PCT/EP2013/061835). When applied on the PED lesion surface, this hypertonic film attracts hypotonic liquid & generates a strong outward liquid flow. Along with protecting the surface, the liquid flow drains away the bacteria & other contaminants thereby reducing the pain and irritation. It also removes the locally present inflammatory cytokines and growth factors to reduce /stop inflammation and pain and to help normalize cell growth. Protective + Antimicrobial + Cleaning + Soothing.

Product Presentation: 50mL Tube containing a viscous, brownish solution for topical application.

Posology: Dose depends on lesion size; 2-3 applications per day in the beginning, then once a day until complete recovery.

Regulatory Status: Due to the mechanical & topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structure:  Class IIa Medical Device in Europe.

Contraindications: Cannot be applied on smooth, non-porous skin; requires light scraping if the skin is keratinized.

Side Effects: None

Clinical Efficacy: Full study published in Int J Modern Pharmaceutical Research, Vol 2, Issue 4, July 2013. ISSN 2319-5878.

Conclusion: 1st topical mechanically cleaning, hydrating, soothing solution to treat open lesions of PSORIASIS, ECZEMA, DERMATITIS

Conclusion: 1st topical multi-factor cleaning gel solution to treat open lesions of
PSORIASIS, ECZEMA, DERMATITIS